ORIGINAL RESEARCH article
Front. Microbiol.
Sec. Microorganisms in Vertebrate Digestive Systems
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1631082
This article is part of the Research TopicThe Role of Gut Microbes and Their Metabolites in Metabolic Diseases: Mechanisms and Therapeutic TargetsView all 5 articles
Dasatinib and Quercetin alleviate type 2 diabetic osteoporosis by regulating serum metabolite and gut microbiome
Provisionally accepted
Junzheng Yang1*
Hua Zhang1Zhuoxu Gu1
Guanghui Zhou1
Gui-Hong Liang2
Lingfeng ZENG2
Jinlong Zhao2
Weiyi Yang2
Jun Liu3
Jian-ke Pan2- 1Guangzhou University of Chinese Medicine, Guangzhou, China
- 2Second College of Guangzhou University of Chinese Medicine, Guangzhou, China
- 3Guangdong Provincial Second Hospital of Traditional Chinese Medicine, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Type 2 diabetic osteoporosis (T2DOP) is a complex metabolic bone disorder characterized by reduced bone density and increased risk of osteoporosis in patients with type 2 diabetes mellitus. The etiology of T2DOP is multifactorial, involving hyperglycemia, insulin resistance, and gut microbiota dysbiosis. Current management strategies for T2DOP typically involve a comprehensive approach, including strict glycemic control, vitamin D and calcium supplementation, anti-osteoporotic medications, increased physical activity, and gut microbiota modulation. This study aimed to investigate the therapeutic potential of the combination of Dasatinib and Quercetin (D + Q), known as senolytics, in treating T2DOP. To elucidate the underlying mechanisms, a well-characterized T2DOP mouse model was established. Bone mass was evaluated using micro-computed tomography and histological staining techniques. Subsequently, the impact of D + Q treatment on gut microbiota composition and complex serum metabolite profiles was comprehensively examined. The results demonstrated that D + Q reshaped gut microbiota, resulting in increased short-chain fatty acid producers (Lachnospiraceae and Bacteroides) and decreased proinflammatory bacteria (Mucispirillum), which were associated with the therapeutic effects in bone-fat balance. Additionally, D + Q treatment enhanced amino acid and short-chain fatty acid metabolism while simultaneously reducing cholesterol and triglyceride levels.
Keywords: senolytics, Bone metabolic diseases, Gut Microbiota, Metabolomics, Type 2 diabete mellitus
Received: 19 May 2025; Accepted: 31 Jul 2025.
Copyright: © 2025 Yang, Zhang, Gu, Zhou, Liang, ZENG, Zhao, Yang, Liu and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Junzheng Yang, Guangzhou University of Chinese Medicine, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.